- Home
- SACH vs MIST Comparison
SACH vs MIST Comparison
Compare SACH & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- MIST
- Stock Information
- Founded
- SACH 2010
- MIST 2003
- Country
- SACH United States
- MIST Canada
- Employees
- SACH N/A
- MIST N/A
- Industry
- SACH Real Estate Investment Trusts
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- MIST Health Care
- Exchange
- SACH Nasdaq
- MIST Nasdaq
- Market Cap
- SACH 79.4M
- MIST 81.5M
- IPO Year
- SACH 2017
- MIST N/A
- Fundamental
- Price
- SACH $1.60
- MIST $1.84
- Analyst Decision
- SACH Buy
- MIST Strong Buy
- Analyst Count
- SACH 2
- MIST 3
- Target Price
- SACH $3.00
- MIST $13.00
- AVG Volume (30 Days)
- SACH 562.1K
- MIST 514.9K
- Earning Date
- SACH 11-14-2024
- MIST 11-12-2024
- Dividend Yield
- SACH 15.05%
- MIST N/A
- EPS Growth
- SACH N/A
- MIST N/A
- EPS
- SACH N/A
- MIST N/A
- Revenue
- SACH $10,951,064.00
- MIST N/A
- Revenue This Year
- SACH N/A
- MIST N/A
- Revenue Next Year
- SACH N/A
- MIST N/A
- P/E Ratio
- SACH N/A
- MIST N/A
- Revenue Growth
- SACH N/A
- MIST N/A
- 52 Week Low
- SACH $1.44
- MIST $1.12
- 52 Week High
- SACH $4.64
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- SACH 23.75
- MIST 62.70
- Support Level
- SACH $1.44
- MIST $1.66
- Resistance Level
- SACH $1.76
- MIST $1.91
- Average True Range (ATR)
- SACH 0.14
- MIST 0.16
- MACD
- SACH -0.04
- MIST 0.00
- Stochastic Oscillator
- SACH 17.51
- MIST 58.73
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).